Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
October 23 2017 - 8:00AM
Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of rare diseases, today announced it received a notice
from the NASDAQ Listing Qualifications Staff on October 20, 2017,
notifying the Company that it regained compliance with NASDAQ's
minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2)
for continued listing on The NASDAQ Capital Market. Accordingly,
Soleno Therapeutics is in compliance with all applicable listing
standards and its common stock will continue to be listed on The
NASDAQ Capital Market and NASDAQ considers the matter closed.
About Soleno Therapeutics,
Inc.
Soleno Therapeutics, Inc. (Soleno) is focused on
the development and commercialization of novel therapeutics for the
treatment of rare diseases. The company is currently
advancing its lead candidate, DCCR, a once-daily oral tablet for
the treatment of PWS, into a Phase III clinical development program
at the end of 2017. Soleno, through its wholly owned
subsidiary, Capnia, Inc., continues to market Capnia’s innovative
medical device, the CoSense® End-Tidal Carbon Monoxide (ETCO)
monitor, which measures ETCO and is used by hospitals to detect
hemolysis in newborns. It is expected that CoSense will be
monetized and will not be a focus for the company in the long
term.
For more information, please visit
www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking
statements that are subject to many risks and uncertainties.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, our ability to
initiate the Phase III clinical development program of DCCR in PWS
by the end of 2017.
We may use terms such as "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should," "approximately" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Although we believe that we have
a reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate may differ materially from the
forward-looking statements contained in this presentation. As a
result of these factors, we cannot assure you that the
forward-looking statements in this presentation will prove to be
accurate. Additional factors that could materially affect actual
results can be found in Soleno’s Form 10-Q filed with the
Securities and Exchange Commission on August 11, 2017, including
under the caption titled "Risk Factors." Soleno expressly disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Sep 2023 to Sep 2024